NMD4C to Develop a List of Canadian Neuromuscular Research Labs to Support Research Collaborations and Training

We are excited to launch an initiative from the NMD4C cell and animal-based NMD research tasks to develop a centralized list of Canadian neuromuscular research labs, providing a key resource to support research collaborations, sharing of expertise, and trainees to pursue mentorship and training in specific techniques or research areas.

In the first stage of this project, we will collect information from Canadian pre-clinical neuromuscular research labs that includes research interests, specialized techniques and expertise, and training capacity. This information will then be published as a centralized list of Canadian neuromuscular research labs on our website.

We need your help to collect this information! We invite all research labs to contribute to this centralized list by having a lab representative complete the collection form here: https://ca.research.net/r/CDN-preclinical-labs.

Organized under the network’s pre-clinical science pillar, the cell and animal-based NMD research tasks work jointly on a variety of projects with the goal of upskilling research trainees and building Canadian neuromuscular research capacity.

Text reading: Cataloguing NMD Basic Research Expertise in Canada, image of researcher pipetting on the right.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.